Paclitaxel liposome encapsulated - INSYS Therapeutics

Drug Profile

Paclitaxel liposome encapsulated - INSYS Therapeutics

Alternative Names: LEP; LEP-ETU; Liposome encapsulated paclitaxel; Liposome entrapped paclitaxel; NeoLipid™ paclitaxel; ONC 0355; Paclitaxel liposomal - INSYS Therapeutics; PNU 914; PNU 93914

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Georgetown University
  • Developer INSYS Therapeutics, Inc
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Cholangiocarcinoma
  • Preclinical Gastric cancer; Ovarian cancer
  • No development reported Breast cancer

Most Recent Events

  • 18 Oct 2016 Phase-II clinical trials in Cervical cancer in USA (IV) (INSYS Therapeutics pipeline October 2016)
  • 18 Oct 2016 Phase-II clinical trials in Cholangiocarcinoma in USA (IV) (INSYS Therapeutics pipeline October 2016)
  • 29 Feb 2016 Preclinical trials in Cervical cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top